Combination Therapy Development for Breast Cancer
Breast cancer remains one of the most prevalent cancers globally, accounting for a significant proportion of cancer-related deaths among women. At Alfa Cytology, our dedicated team of biologists and oncology experts has been at the forefront of exploring innovative combination therapies to address this critical healthcare concern.
Introduction of Combination Therapy for Breast Cancer
Traditional monotherapies often fall short due to issues like drug resistance, toxicity, and insufficient effectiveness, particularly in advanced or metastatic cases. Consequently, combination therapies—utilizing two or more therapeutic agents targeting different pathways—have emerged as a promising strategy to enhance treatment outcomes.
Fig.1 Schematic illustration of current treatments for breast cancer. (Wang Y., et al. 2022)
Combination therapies can significantly improve survival rates by addressing the multifaceted nature of breast cancer. For instance, combining molecular-targeted therapies with endocrine treatments has shown enhanced efficacy in hormone receptor-positive subtypes, where resistance to single-agent therapies is common. Additionally, immunotherapy has gained traction, particularly for TNBC, which lacks effective targeted treatments.
Combination Therapy Development for Breast Cancer
Ongoing clinical trials of novel combination therapies for breast cancer are paving the way for more effective treatment options. By targeting multiple pathways and utilizing diverse therapeutic modalities, these trials hold the potential to improve outcomes.
| NCT | Category | Therapeutics | Phase |
| NCT02764541 | Cyclin-dependent Kinase Inhibitors + Endocrine Therapy | Letrozole + Tamoxifen + Palbociclib + Endocrine Therapy |
|
| NCT03113825 | E-cadherin/ROS1 Inhibitor | Crizotinib + Fulvestrant | |
| NCT04551495 | Tyrosine Kinase Inhibitor + Hormone Therapy | Tyrosine Kinase Inhibitor + Letrozole + Goserelin | |
| NCT05041101 | Anti-inflammatory Drug + Microtubule Inhibitor | Grapiprant and Eribulin | |
| NCT03202316 | PD-L1 Antibody + Kinase Inhibitors + Microtubule Inhibitor | Atezolizumab + Cobimetinib + Eribulin | |
| NCT01036087 | Anti-EGFR Antibody + Mitotic Inhibitor + Cytostatics | Panitumumab + Nab-paclitaxel + Carboplatin |
Our Services
At Alfa Cytology, we specialize in the development and optimization of combination therapies for breast cancer. Our comprehensive range of services includes:
- Combination Immunochemotherapy
- Synergistic Ferroptosis-starvation Therapy
- Combination of Photodynamic Therapy (PDT) with Immunotherapy
- Combination of Sonodynamic Therapy (SDT) with Chemotherapy
- Combination of Radiotherapy with Targeted Therapy
- Combination Chemo-photodynamic Therapy
- Combination of Chemodynamic Therapy (CDT) with Photothermal Therapy (PTT)
- And More
For inquiries about our services or to discuss potential collaborations in combination therapy development for breast cancer, please contact us at Alfa Cytology. Our dedicated team of experts is eager to assist in advancing your research objectives and contributing to the fight against breast cancer.
Reference
- Wang Y., Minden A. Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. Int J Mol Sci. 2022, 23(19): 11046.